15mg依度沙班在老年房颤患者三个年龄层的临床结局:ELDERCARE-AF预设亚组分析
该预设亚组分析基于ELDERCARE-AF随机双盲试验,纳入984例不适合标准剂量口服抗凝药的80岁以上日本房颤患者,比较15mg依度沙班与安慰剂在三个年龄层(80-84、85-89、≥90岁)的疗效与安全性。结果显示,依度沙班在各年龄层一致降低卒中或系统性栓塞事件率,与年龄无交互作用,大出血数值升高但无统计学差异。
要点
- 15mg依度沙班在80岁以上不适合标准抗凝的房颤患者中,各年龄层一致降低卒中或系统性栓塞风险。
- 安慰剂组卒中或系统性栓塞事件率随年龄增长而升高,≥90岁组达10.1%/患者年。
- 大出血及大出血或临床相关非大出血事件在依度沙班组数值较高,但差异无统计学意义且与年龄无交互作用。
核心结论
- 在80岁以上不适合标准剂量口服抗凝药的日本房颤患者中,每日一次15mg依度沙班在预防卒中或系统性栓塞方面优于安慰剂,且三个年龄层(包括≥90岁)结果一致。
- 依度沙班组大出血及大出血或临床相关非大出血事件数值上高于安慰剂,但差异未达统计学显著性,且与年龄无交互作用。
- 依度沙班组与安慰剂组在全因死亡事件率上各年龄层均无差异。
研究设计与样本
- ELDERCARE-AF试验的预设亚组分析,为3期随机双盲安慰剂对照试验,于2016年8月5日至2019年12月27日进行。
- 纳入80岁以上、不适合标准剂量口服抗凝药的房颤患者,原因包括肌酐清除率<30 mL/min、体重≤45 kg、关键器官出血史、连续使用非甾体抗炎药或联用抗血小板药。
- 患者从日本164家医院随机招募,按1:1随机分配至依度沙班15mg每日一次或安慰剂组。
- 共纳入984例患者,平均(SD)年龄:80-84岁组82.2(1.4)岁,85-89岁组86.8(1.4)岁,≥90岁组92.3(2.1)岁;女性565例(57.4%)。
主要发现
- 安慰剂组卒中或系统性栓塞估计事件率随年龄增长:80-84岁组3.9%(1.2%)/患者年(n=181),85-89岁组7.3%(1.7%)/患者年(n=184),≥90岁组10.1%(2.5%)/患者年(n=127)。
- 大出血及大出血或临床相关非大出血事件在依度沙班组数值较高,但差异未达统计学显著性,且与年龄无交互作用。
- 全因死亡事件率在依度沙班组与安慰剂组各年龄层均无差异。
关键数值与推荐
- 主要疗效终点为卒中或系统性栓塞复合终点;主要安全终点为ISTH定义的大出血。
- 不适合标准剂量口服抗凝药的条件包括:肌酐清除率<30 mL/min、体重≤45 kg、关键器官出血史、连续使用非甾体抗炎药或联用抗血小板药。
临床怎么用
- 对于80岁以上、因出血风险高或不适合标准剂量口服抗凝药的房颤患者,可考虑使用15mg依度沙班每日一次进行卒中预防。
- 在≥90岁患者中,15mg依度沙班同样显示获益,但需关注出血风险,尽管大出血增加未达统计学显著性。
局限性
- 本研究为日本人群的预设亚组分析,结果外推至其他种族或地区需谨慎。
- 各年龄层样本量较小,尤其是≥90岁组安慰剂仅127例,效应估计的置信区间较宽。
- 研究仅评估15mg依度沙班,未与其他剂量或抗凝药直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Long-term use of oral anticoagulants (OACs) is necessary for stroke prevention in patients with atrial fibrillation (AF). The effectiveness and safety of OACs in extremely older patients (ie, aged 80 years or older) with AF and at high risk of bleeding needs to be elucidated. OBJECTIVE: To examine the effects of very low-dose edoxaban (15 mg) vs placebo across 3 age strata (80-84 years, 85-89 years, and ≥90 years) among patients with AF who were a part of the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial. DESIGN, SETTING, AND PARTICIPANTS: This prespecified subanalysis of a phase 3, randomized, double-blind, placebo-controlled trial was conducted from August 5, 2016, to December 27, 2019. Patients with AF aged 80 years or older who were not considered candidates for standard-dose OACs were included in the study; reasons these patients could not take standard-dose OACs included low creatinine clearance (<30 mL per minute), low body weight (≤45 kg), history of bleeding from critical organs, continuous use of nonsteroidal anti-inflammatory drugs, or concomitant use of antiplatelet drugs. Eligible patients were recruited randomly from 164 hospitals in Japan and were randomly assigned 1:1 to edoxaban or placebo. INTERVENTIONS: Edoxaban (15 mg once daily) or placebo. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the composite of stroke or systemic embolism. The primary safety end point was International Society on Thrombosis and Hemostasis-defined major bleeding. RESULTS: A total of 984 patients (mean [SD] age: age group 80-84 years, 82.2 [1.4] years; age group 85-89 years, 86.8 [1.4] years; age group ≥90 years, 92.3 [2.1] years; 565 women [57.4%]) were included in this study. In the placebo group, estimated (SE) event rates for stroke or systemic embolism increased with age and were 3.9% (1.2%) per patient-year in the group aged 80 to 84 years (n = 181), 7.3% (1.7%) per patient-year in the group aged 85 to 89 years (n = 184), and 10.1% (2.5%) per patient-year in the group aged 90 years or older (n = 127). A 15-mg dose of edoxaban consistently decreased the event rates for stroke or systemic embolism with no interaction with age (80-84 years, hazard ratio [HR], 0.41; 95% CI, 0.13-1.31; P = .13; 85-89 years, HR, 0.42; 95% CI, 0.17-0.99; P = .05; ≥90 years, HR, 0.23; 95% CI, 0.08-0.68; P = .008; interaction P = .65). Major bleeding and major or clinically relevant nonmajor bleeding events were numerically higher with edoxaban, but the differences did not reach statistical significance, and there was no interaction with age. There was no difference in the event rate for all-cause death between the edoxaban and placebo groups in all age strata. CONCLUSIONS AND RELEVANCE: Results of this subanalysis of the ELDERCARE-AF randomized clinical trial revealed that among Japanese patients aged 80 years or older with AF who were not considered candidates for standard OACs, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism consistently across all 3 age strata, including those aged 90 years or older, albeit with a higher but nonstatistically significant incidence of bleeding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02801669.
引用
- Kuroda, Tamiya, Nose, et al. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 35416910. doi:10.1001/jamacardio.2022.0480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。